ArticleEClinicalMedicine2020

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial.

Katia Abarca et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.